Table 1. Baseline Table
All Patients (n=112 648)No ACEI/ARB (n=29 357)ACEI/ARB (n=83 291)P Value
Demographics
Age, median (IQR), y72 (62–81)74 (62–83)71 (62–79)<0.001
Sex, women39 987 (35.5)11 729 (40.0)28 258 (33.9)<0.001
Smoking, n=106 88625 714 (24.1)6451 (23.8)19 263 (24.1)<0.001
Body mass index, median (IQR), n=97 20426 (24–29)25 (23–28)27 (24–29)<0.001
Admission year<0.001
200616 949 (15.0)5783 (19.7)11 166 (13.4)
200717 264 (15.3)5177 (17.6)12 087 (14.5)
200816 311 (14.5)4453 (15.2)11 858 (14.2)
200915 387 (13.7)3877 (13.2)11 510 (13.8)
201015 466 (13.7)3469 (11.8)11 997 (14.4)
201115 616 (13.9)3287 (11.2)12 329 (14.8)
201215 655 (13.9)3311 (11.3)12 344 (14.8)
Comorbidities and presentation at admission
Diabetes mellitus27 149 (24.1)4959 (16.9)22 190 (26.6)<0.001
Hypertension67 436 (59.9)13 571 (46.2)53 865 (64.7)<0.001
MI29 330 (26.0)7087 (24.1)22 243 (26.7)<0.001
CHF12 039 (10.7)2903 (9.9)9136 (11.0)<0.001
Peripheral vascular disease6143 (5.5)1618 (5.5)4525 (5.4)0.61
Stroke13 038 (11.6)3618 (12.3)9420 (11.3)<0.001
Any bleeding7390 (6.6)2174 (7.4)5216 (6.3)<0.001
Chronic obstructive pulmonary disease7855 (7.0)2262 (7.7)5593 (6.7)<0.001
Dementia616 (0.5)282 (1.0)334 (0.4)<0.001
Cancer diagnosis within 3 years3160 (2.8)1033 (3.5)2127 (2.6)<0.001
Previous PCI12 727 (11.3)2667 (9.1)10 060 (12.1)<0.001
Previous CABG9461 (8.4)2100 (7.2)7361 (8.8)<0.001
Hospital course
STEMI36 472 (32.4)6949 (23.7)29 523 (35.4)<0.001
PCI63 821 (56.7)12 621 (43.0)51 200 (61.5)<0.001
CABG3935 (3.5)1181 (4.0)2754 (3.3)<0.001
Creatinine, median (IQR), μmol/L, n=110 14383 (70–102)84 (70–106)83 (70–100)<0.001
Decompensated heart failure (Killip ≥II), n=108 07815 524 (14.4)3886 (13.8)11 638 (14.6)0.003
LVEF <50%, n=82 02635 679 (43.5)4924 (27.1)30 755 (48.2)<0.001
CHF (including history of)43 165 (38.3)7136 (24.3)36 029 (43.3)<0.001
New‐onset AF9853 (8.9)2635 (9.2)7218 (8.9)0.08
AF (including history of)21 555 (19.1)5936 (20.2)15 619 (18.8)<0.001
Discharge medication
Aspirin104 283 (92.8)26 459 (90.5)77 824 (93.6)<0.001
P2Y12 inhibitors86 889 (77.2)19 770 (67.6)67 119 (80.6)<0.001
Oral anticoagulants7921 (7.0)1655 (5.7)6266 (7.5)<0.001
β‐blockers100 285 (89.1)24 537 (83.8)75 748 (91.0)<0.001
Calcium‐channel blockers17 711 (15.7)4327 (14.8)13 384 (16.1)<0.001
Digoxin3613 (3.2)1016 (3.5)2597 (3.1)0.003
Diuretics37 220 (33.1)8834 (30.2)28 386 (34.1)<0.001
Nitrates19 301 (17.2)5874 (20.1)13 427 (16.2)<0.001
Statins94 871 (84.3)21 382 (73.1)73 489 (88.3)<0.001
  • Patient characteristics, admission year, and clinical and in‐hospital characteristics of acute myocardial infarction patients in relation to treatment with ACEI and/or ARB at discharge. Demographic and baseline characteristics were reported using percentages for categorical variables or with median and IQR for continuous variables (as noted). ACEI indicates angiotensin‐converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin II receptor blockers; CABG, coronary artery bypass grafting; CHF, congestive heart failure; IQR, interquartile range; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐segment elevation myocardial infarction.